FDA Hosts Public Workshop on Gastroenterology Regulatory Endpoints and Therapeutic Advancement

Summary

The FDA is hosting a 4-day public workshop to discuss regulatory endpoints for drug development in diseases such as eosinophilic esophagitis, inflammatory bowel disease, and parenteral nutrition-associated liver disease, with the goal of advancing therapeutics in these areas.